Not applicable.
1. Field of the Invention
Embodiments of the present invention are directed to positive airway pressure devices and methods, for example continuous positive airway pressure (CPAP) devices. More particularly, embodiments of the invention are directed to positive airway pressure devices and methods where the flow and/or pressure through each nostril or naris and the patient's mouth may be individually controlled.
2. Background of the Invention
Sleep disordered breathing is common throughout the population. Some sleep disorders may be attributable to disorders of the respiratory tract. Sleep apnea may be a disorder where a person temporarily stops breathing during sleep. A hypopnea may be a period of time where a person's breathing becomes abnormally slow or shallow. In some cases, a hypopnea may precede an apnea event.
Although hypopneas and apneas may have multiple causes, one trigger for these type events may be full or partial blockages in the respiratory tract. In particular, in some patients the larynx may collapse due to forces of gravity and/or due to forces associated with lower pressure in the larynx than outside the body. A collapse of the pharynx, larynx, upper airway or other soft tissue in the respiratory tract may thus cause a full or partial blockage, which may lead to a hypopnea or apnea event.
One method to counter collapse of the larynx may be the application of positive airway pressure, possibly by using a CPAP machine. This may be accomplished in the related art by placing a mask over at least the patient's nose, and providing within the mask a pressure communicated to the pharynx, larynx, or upper airway. The pressure within the pharynx, larynx, or upper airway may be greater than the pressure outside the body, thus splinting the airway open.
CPAP machines are concerned only with the pressure of the gas supplied at the nostrils of the patient. However, gases flowing from a region of high pressure to a region of low pressure will take the path of least resistance. Thus, breathable gases provided to a patient in the related art may flow only or predominantly through an open nostril or naris. Forcing or allowing all the gas flow to move through a single naris may cause patient discomfort, both because of the volume of the flow and because of the drying effects experienced by the naris through which the gas moves. The flow problem may be exacerbated by a patient attempting to mouth breath while using a CPAP machine.
The problems noted above are solved in large part by a method and system of individually controlling positive airway pressure of a patient's nares. Some exemplary embodiments may be a method comprising applying therapeutic gas pressure within a first naris of a patient during respiration, and applying therapeutic gas pressure within a second naris of the patient during the respiration. The therapeutic gas pressures applied to each naris are different.
Other exemplary embodiments may be a system comprising a first blower having an outlet port fluidly coupled to a first pressure transducer (wherein the first blower operatively couples to a first naris of a patient), and a second blower having an outlet port fluidly coupled to a second pressure transducer (wherein the second blower operatively couples to a second naris of the patient).
Yet further exemplary embodiments may be a method comprising applying a therapeutic gas flow into a first naris of a patient during an inhalation (the therapeutic gas flow comprising substantially all the gas inspired through the first naris during the inhalation), and applying a therapeutic gas flow into a second naris of a patient during the inhalation (the therapeutic gas flow comprising substantially all the gas inspired through the second naris during the inhalation). The therapeutic gas flow into each naris is achieved by differing applied pressures within each naris.
Other exemplary embodiments may be a system comprising a first blower fluidly coupled to an outlet port through a first flow sensor (wherein the first blower and first flow sensor operatively couple to a first naris of a patient and provide substantially all the gas inspired through the first naris during an inhalation), and a second blower fluidly coupled to an outlet port through a second flow sensor (wherein the second blower and second flow sensor operatively couple to a second naris of the patient and provide substantially all the gas inspired through the second naris during the inhalation). A pressure applied by the first blower to the first naris to achieve a desired gas flow is different that a pressure applied by the second blower to the second naris to achieve a desired gas flow.
Yet further exemplary embodiments may be a method comprising selectively supplying positive airway pressure to one or both of a patient's nares during an inhalation, and supplying positive airway pressure to the patient's mouth during the inhalation.
Other exemplary embodiments may be a system comprising a first blower fluidly coupled to an outlet port (wherein the first blower operatively couples to a first naris of a patient and provides substantially all the gas inspired through the first naris during an inhalation), and a second blower fluidly coupled to an outlet port, wherein the second blower operatively couples to a mouth of the patient and provides substantially all the gas inspired through the mouth during the inhalation.
Yet further exemplary embodiments may be a method comprising providing therapeutic gas at a first pressure at a device end of a positive airway pressure mask, the first pressure higher than a prescribed pressure for the patient such that therapeutic gas pressure at a patient end of the mask is substantially the same as the prescribed pressure.
Other exemplary embodiments may be a system comprising a source of therapeutic gas under pressure, and a positive airway pressure mask having a device end and a patient end, the device end coupled to the source of therapeutic gas, and the patient end coupled to an airway of the patient. The system compensates for resistance to gas flow of the mask by increasing the pressure of the therapeutic gas at the device end of the mask above the patient's prescribed titration pressure.
Yet further exemplary embodiments may be a respiratory mask comprising a first nostril interface operable to substantially seal to a first nostril of a patient, a second nostril interface operable to substantially seal to a second nostril of the patient, an oral mask operable to substantially seal to the mouth of the patient, a first supply tube that penetrates the oral mask and fluidly couples to the first nostril interface (the first supply tube is operable to fluidly couple to a first supply port of a positive airway pressure device), a second supply tube that penetrates the oral mask and fluidly couples to the second nostril interface (the second supply tube is operable to fluidly couple to a second supply port of the positive airway pressure device), and a third supply tube fluidly coupled to the oral mask (the third supply tube operable to fluidly couple to a third supply port of the positive airway pressure device).
Other exemplary embodiments may be a respiratory mask comprising a first nostril interface operable to substantially seal to a first nostril of a patient, a second nostril interface operable to substantially seal to a second nostril of the patient, a first supply tube fluidly coupled to the first nostril interface, the first supply tube is operable to fluidly couple to a first supply port of a positive airway pressure device, and a second supply tube fluidly coupled to the second nostril interface, the second supply tube is operable to fluidly couple to a second supply port of the positive airway pressure device.
The disclosed devices and methods comprise a combination of features and advantages which enable it to overcome the deficiencies of the prior art devices. The various characteristics described above, as well as other features, will be readily apparent to those skilled in the art upon reading the following detailed description, and by referring to the accompanying drawings.
For a detailed description of the preferred embodiments of the invention, reference will now be made to the accompanying drawings in which:
Certain terms are used throughout the following description and claims to refer to particular system components. This document does not intend to distinguish between components that differ in name but not function.
In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . ”. Also, the term “couple” or “couples” is intended to mean either an indirect or direct connection. Thus, if a first device couples to a second device, that connection may be through a direct connection, or through an indirect connection via other devices and connections.
Further, use of the terms “pressure,” “applying a pressure,” and the like shall be in reference herein, and in the claims, to gauge pressure rather than absolute pressure. Thus, application of a negative pressure shall mean a pressure below atmospheric.
Consider, for purposes of explanation of the relationship between pressure and air flow, the system illustrated in FIG. 1.
Further consider that each tube 18, 22 has coupled thereto a pressure transducer 26, 28 respectively. The pressure transducers are for purposes of illustration, and may not be required in some embodiments of the invention. Each of the pressure transducers 26, 28 may be capable of reading a pressure within the respective tube 18, 22. Blowers 10, 12 may be operated in a pressure control mode. While the controlled pressure within each tube may be different, for purposes of explanation consider that the pressure within each tube 18, 22 are controlled to be the same. Further consider that the common chamber 20 is at a low pressure, such as vented to atmosphere. Thus, because of the pressure differentials between the tubes 18, 22 and the common chamber 20, there may be an airflow from the tubes 18, 22 into the chamber 20 (as indicated by the arrows in FIG. 1). However, in spite of the fact that the pressure within the tubes 18, 22 may be the same in this example, the air flow may be different. That is, orifice 24 may provide a resistance to air flow from the tube 18 into the common chamber 20 that is not experienced by air flow moving through tube 22. In particular, because of the restriction caused by orifice 24, the air flow through tube 18 may be less than the air flow through tube 22. Thus, even for the same pressure within the tubes 18, 22, the air flow through those tubes may be different.
Now consider that the blowers 10, 12 are operated in a flow control mode, with each blower attempting to maintain equivalent air flow regardless of required pressure. In order to maintain the desired flow, blower 10 may need to develop a higher pressure to overcome the restriction of orifice 24 than the pressure that may be required of blower 12 for the same flow. With these principles in mind, the specification now turns to a discussion of the method and related systems for providing positive airway pressure to a patient.
In accordance with embodiments of the invention, the positive airway pressure device 30 controls pressure and/or flow to each naris of a patient individually. In some embodiments, therapeutic gas flow to the patient may be divided among the nares so as not to force any one naris to carry all the therapeutic gas flow. In order to ensure that each naris is carrying at least part of the therapeutic gas flow, the flow path for each naris may need individual pressure and/or flow control. In alternative embodiments, the therapeutic gas flow through each naris may be individually controlled to be different.
Control of the pressure, and therefore the therapeutic gas flow may take many forms. In one embodiment, the pressure may be controlled by selectively controlling blower speed, e.g. by controlling the speed of the motor coupled to the blower. In alternative embodiments, the blowers 32, 40 may be operated at a constant speed and the pressure provided to the patient may be controlled by pressure control valves 48, 50 for the blowers 32, 40 respectively. In yet other embodiments, a combination of controlling the blower speed in a pressure control valve may be utilized.
The control system 60 also may comprise a microcontroller 70 coupled to the motor speed control circuit 66 and 68. The microcontroller 70 may be any suitable microcontroller or microprocessor programmed to provide an indication to each of the motor speed control circuits 66 and 68 of a desired motor speed. Determining a motor speed may be based, in some embodiments, on pressures read by the microcontroller 70 from the pressure transducers 36 and 44. In other embodiments, the desired motor speeds may be set based on gas flows measured by the flow sensors 34 and 42. In these flow control embodiments, pressure transducers may not be required. Although microprocessor control is preferred, the positive airway pressure device may be equivalently implemented with an analog control system.
In accordance with some embodiments of the invention, the microcontroller 70 may be provided with a prescribed titration pressure, possibly by way of a dial-type input (not shown) or some other form of user interface (not shown). Based on the prescribed pressure, the microcontroller may ramp the speed control signal passed to each of the motor speed control circuits 66 and 68 to achieve the desired pressure. If a naris is severely congested or otherwise blocked (e.g. by a tumor or polyp), however, therapeutic gas flow may move only through an open naris at the prescribed titration pressure. Moreover, throughout the night, the restriction or resistance to flow experienced within each naris may change, e.g. as a function of congestion experienced within each naris or as a function of an amount of swelling of the soft tissue within each naris. Thus, even at the prescribed pressure the patient may receive inadequate therapeutic gas. A positive airway pressure device in accordance with embodiments of the invention may measure the therapeutic gas flow through each naris, possibly by reading signals from the flow sensors 34 and 42. If the therapeutic gas flow to the nares is at least partially evenly divided among the nares, no further action may be required other than to control pressure. If, however, the measured flow is not at least partially balanced, some embodiments of the device 30 may attempt to equalize the flow by changing the pressure applied to one naris.
A positive airway pressure device in accordance with embodiments of the invention may at least momentarily increase the pressure to the blocked or partially blocked naris in an attempt to establish a flow. Once established, the flow of therapeutic gas through the naris may act as a pneumatic splint (in the much the same way that the flow may act to splint the larynx to reduce the hypopnea and apnea events), and therefore the applies pressure may be reduced after opening.
Alternative embodiments may be concerned with the prescribed titration pressure. In particular, a doctor may prescribe a certain pressure found to achieve the desired results in a patient. However the inventors of the current specification have found that the masks, and related tubing, used to provide continuous positive airway pressure in the related art have a resistance to the flow of therapeutic gas (e.g. air or oxygen enriched air). This resistance to flow results in a pressure drop across the mask and tubing such that the patient may not be provided the desired titration pressure at the mask.
Notwithstanding the calculation of resistance to airflow prior to application of the prescribed pressure to the patient's airways, at least some embodiments of the invention may also adjust the pressure supplied at the device end to compensate for resistance to airflow changes during use. In particular, the relative humidity (related to dew point) of the therapeutic gas moving through the tubing and respiratory mask affects the resistance to flow experienced by the gas. The higher the relative humidity, the higher the resistance to flow experienced by the gas. Thus, embodiments of the invention monitor relative humidity of the supplied therapeutic gas, and as the relative humidity changes the pressure applied by the device 30 may likewise change to ensure the pressure provided within the patient's airway during inhalation is substantially the titration pressure prescribed.
In yet further alternative embodiments, medical doctors may prescribe a total therapeutic gas flow rather than a titration pressure. In these circumstances, the positive airway pressure device 30, possibly using the control system illustrated in
Dividing the air flow substantially evenly between the nares may be more comfortable for the patient. A device that is capable of adjusting its pressure to ensure airflow may more accurately provide that airflow in spite of the fact that the resistance to flow through a naris may change significantly over the course of a night. Further, dividing the therapeutic gas flow among the nares substantially evenly may reduce discomfort associated with drying of the nasal cavities by the air flow through the nares (in comparison to forcing the air flow through a single naris).
Embodiments of the invention may not, however, increase pressure indefinitely in an attempt to evenly distribute the air flow across the nares. In particular, the microcontroller 70 may have an upper limit of pressure, for example 20 cm H2O, that it may apply to a particular naris in an attempt to open the naris or provide a desired air flow. If therapeutic gas flow has not been established or the naris has not been opened upon reaching an upper limit pressure, the microcontroller 70 may resort to providing the necessary therapeutic gas flow to the open naris, and possibly reporting the blockage by means of a user interface (not shown). In yet further embodiments, discussed below, the microcontroller 70 may augment the pressure and/or flow provided to the only open naris of a patient with delivery of therapeutic gas to the patient's mouth. If over the course of a treatment (for example overnight) the formerly clogged naris becomes less resistant to therapeutic gas flow, the microcontroller may begin providing gas flow at that point.
In yet other alternative embodiments, the positive airway pressure device 60 may be coupled to the patient's nares, but may initially refrain from providing pressure and/or flow. Thus, in an initial state the positive airway pressure device 60 may merely monitor flow through the nares, and become operational only if a disruption in flow occurs. For example, if the patient changes sleeping position an obstruction may arise, and in this case the device 60 may activate one or more blowers to apply airway pressure and/or ensure therapeutic gas flow. As yet another example, the patient may develop a congestion in one or both nares, and upon detecting the blockage in the form of congestion the device 60 may activate one or more blowers to apply airway pressure and/or ensure therapeutic gas flow. In another example, the device 60 may monitor flow through the nares, and upon detecting the patient is snoring (e.g. by detecting rapid undulations in the measure flow) may activate one or more blowers to apply airway pressure and/or ensure therapeutic gas flow. In yet other embodiments, the device 60 may initially provide the patient air filtered for allergens, and may provide therapeutic gas at some later time, if required.
Referring again to
Thus, in accordance with these alternative embodiments the therapeutic gas flow and/or pressure to each of the patient's nostrils and mouth may be individually controlled. In these embodiments, positive airway pressure may be applied to the nostrils only, to the mouth only, or to a combination of one or more nostrils and the mouth depending on the particular situation of the patient. Consider, for example, a patient being provided positive airway pressure during inhalation only to the nostrils. As one nostril becomes congested, the positive airway pressure device 30 may be unable to provide sufficient flow through the remaining nostril or naris to prevent apnea or hypopnea events. In this case, in accordance with embodiments of the invention, additional positive airway pressure may be provided to the patient by way of the mouth. Relatedly, a physical abnormality, tumor or polyp may permanently block air flow through one nostril of a patient, and thus positive airway pressure may be supplied to the patient through the open nostril as well as the mouth.
Applying positive airway pressure individually through the nostrils assumes that the patient does not mouth breathe. In some cases, however, patients (especially during sleep) may transition between nasal only breathing and a combination nasal and mouth breathing. For those patients operating under a titration pressure, opening of the mouth increases flow through one or more of the nostrils as part of the gas escapes through the mouth, even during an inhalation. This increase in flow may likewise increase the nasal irritation associated with that flow. Moreover, the escape of the therapeutic gas through the mouth may mean that insufficient therapeutic gas reaches the lungs (apart from the benefits of the positive airway pressure). In accordance with alternative embodiments of the invention, initially the blower 41 may be turned off and the flow sensor 43 may be coupled to the mouth of the patient. During periods of time when the patient's mouth is closed, the positive airway pressure device 30 may selectively control therapeutic gas pressure and/or flow using the blowers 32, 40 and related devices. When the patient opens the mouth and begins to mouth breathe, the positive airway pressure device 30 may take corrective action. In some embodiments, the positive airway pressure device 30 may activate blower 41 to supply therapeutic gas to the mouth at a particular pressure. In these embodiments, the positive airway pressure device 30 may attempt to provide a pneumatic block to airflow through the mouth. In yet further embodiments, upon detecting mouth breathing the positive airway pressure device may provide the flow of therapeutic gas and/or pressure to the patient at least partially through the open mouth.
The embodiments discussed to this point have been in relation to providing positive airway pressure to a patient during inhalation. Related art continuous airway pressure (CPAP) devices provide the positive airway pressure even during exhalation. However, in accordance with at least some embodiments of the invention the positive airway pressure device 30 reduces the pressure within the patient's airways to ease the patient effort required to exhale. The reduction in airway pressure may take many forms. In some embodiments, the airway pressure may be reduced yet the pressure within the airways may still be above atmospheric or ambient pressure. In yet other embodiments, the application of pressure may be removed entirely such that the airways experience substantially atmospheric pressure during the exhalation process. In yet further embodiments, a negative pressure (vacuum) may be applied to assist the patient with the exhalation process. Referring again to
Referring again briefly to
The respiratory masks of
Though the masks illustrated in the figures may be preferred, any mechanism by which the delivery tubes are fluidly coupled to their respective naris may be used without departing form the scope and spirit of the invention.
The above discussion is meant to be illustrative of the principles and various embodiments of the present invention. Numerous variations and modifications will become apparent to those skilled in the art once the above disclosure is fully appreciated. It is intended that the following claims be interpreted to embrace all such variations and modifications.
This specification claims the benefit of the provisional application Ser. No. 60/488,615 filed Jul. 18, 2003, titled, “Method And System For Controlling Therapeutic Gas Flow To Each Naris Of A Patient In Positive Airway Pressure Applications,” which application is incorporated by reference herein as if reproduced in full below.
Number | Name | Date | Kind |
---|---|---|---|
4922900 | Kiske et al. | May 1990 | A |
5117819 | Servidio et al. | Jun 1992 | A |
5148802 | Sanders et al. | Sep 1992 | A |
5161525 | Kimm et al. | Nov 1992 | A |
5239995 | Estes et al. | Aug 1993 | A |
5269296 | Landis | Dec 1993 | A |
5313937 | Zdrojkowski | May 1994 | A |
5433193 | Sanders et al. | Jul 1995 | A |
5458137 | Axe et al. | Oct 1995 | A |
5477852 | Landis et al. | Dec 1995 | A |
5492113 | Estes et al. | Feb 1996 | A |
5522382 | Sullivan et al. | Jun 1996 | A |
RE35295 | Estes et al. | Jul 1996 | E |
5535738 | Estes et al. | Jul 1996 | A |
5537997 | Mechlenburg et al. | Jul 1996 | A |
5540219 | Mechlenburg et al. | Jul 1996 | A |
5551418 | Estes et al. | Sep 1996 | A |
RE35339 | Rapoport | Oct 1996 | E |
5645054 | Cotner et al. | Jul 1997 | A |
5655522 | Mechlenburg et al. | Aug 1997 | A |
5657752 | Landis et al. | Aug 1997 | A |
5682878 | Ogden | Nov 1997 | A |
5685296 | Zdrojkowski et al. | Nov 1997 | A |
5687715 | Landis et al. | Nov 1997 | A |
5740795 | Brydon | Apr 1998 | A |
5794614 | Gruenke et al. | Aug 1998 | A |
5794615 | Estes | Aug 1998 | A |
5803065 | Zdrojkowski et al. | Sep 1998 | A |
5803066 | Rapoport et al. | Sep 1998 | A |
5891023 | Lynn | Apr 1999 | A |
5901704 | Estes et al. | May 1999 | A |
5904141 | Estes et al. | May 1999 | A |
5937855 | Zdrojkowski et al. | Aug 1999 | A |
5957133 | Hart | Sep 1999 | A |
5970975 | Estes et al. | Oct 1999 | A |
6029664 | Zdrojkowski et al. | Feb 2000 | A |
6041780 | Richard et al. | Mar 2000 | A |
6085747 | Axe et al. | Jul 2000 | A |
6105575 | Estes et al. | Aug 2000 | A |
6112745 | Lang | Sep 2000 | A |
6138675 | Berthon-Jones | Oct 2000 | A |
6152129 | Berthon-Jones | Nov 2000 | A |
6182657 | Brydon et al. | Feb 2001 | B1 |
6213119 | Brydon et al. | Apr 2001 | B1 |
6223064 | Lynn et al. | Apr 2001 | B1 |
6237593 | Brydon | May 2001 | B1 |
6240921 | Brydon et al. | Jun 2001 | B1 |
6253764 | Calluaud | Jul 2001 | B1 |
6253766 | Niles et al. | Jul 2001 | B1 |
6279569 | Berthon-Jones | Aug 2001 | B1 |
6299581 | Rapoport et al. | Oct 2001 | B1 |
6302105 | Wickham et al. | Oct 2001 | B1 |
6305374 | Zdrojkowski et al. | Oct 2001 | B1 |
6318365 | Vogele et al. | Nov 2001 | B1 |
6328753 | Zammit | Dec 2001 | B1 |
6332463 | Farrugia et al. | Dec 2001 | B1 |
6342039 | Lynn et al. | Jan 2002 | B1 |
6342040 | Starr et al. | Jan 2002 | B1 |
6345619 | Finn | Feb 2002 | B1 |
6363933 | Berthon-Jones | Apr 2002 | B1 |
6367474 | Berthon-Jones et al. | Apr 2002 | B1 |
6397841 | Kenyon et al. | Jun 2002 | B1 |
6398739 | Sullivan et al. | Jun 2002 | B1 |
6401713 | Hill et al. | Jun 2002 | B1 |
6427689 | Estes et al. | Aug 2002 | B1 |
6484719 | Berthon-Jones | Nov 2002 | B1 |
6502572 | Berthon-Jones et al. | Jan 2003 | B1 |
6526974 | Brydon et al. | Mar 2003 | B1 |
6530372 | Madaus et al. | Mar 2003 | B1 |
6532956 | Hill | Mar 2003 | B1 |
6532960 | Yurko | Mar 2003 | B1 |
6539940 | Zdrojkowski et al. | Apr 2003 | B1 |
6553992 | Berthon-Jones et al. | Apr 2003 | B1 |
6575163 | Berthon-Jones | Jun 2003 | B1 |
6588422 | Berthon-Jones et al. | Jul 2003 | B1 |
6591834 | Colla et al. | Jul 2003 | B1 |
6609517 | Estes et al. | Aug 2003 | B1 |
6622724 | Truitt et al. | Sep 2003 | B1 |
6626174 | Genger et al. | Sep 2003 | B1 |
6626176 | Madaus et al. | Sep 2003 | B1 |
6629527 | Estes et al. | Oct 2003 | B1 |
6635021 | Sullivan et al. | Oct 2003 | B1 |
6640806 | Yurko | Nov 2003 | B1 |
6659101 | Berthon-Jones | Dec 2003 | B1 |
6705315 | Sullivan et al. | Mar 2004 | B1 |
6752151 | Hill | Jun 2004 | B1 |
20020029004 | Starr et al. | Mar 2002 | A1 |
20040074492 | Berthon-Jones | Apr 2004 | A1 |
Number | Date | Country | |
---|---|---|---|
20050011523 A1 | Jan 2005 | US |
Number | Date | Country | |
---|---|---|---|
60488615 | Jul 2003 | US |